Symbiomix Therapeutics’ Bacterial Vaginosis Treatment Wins FDA Nod

September 21, 2017

The FDA approved Symbiomix Therapeutics’ treatment for bacterial vaginosis.

Solosec is the first single-dose oral therapy for the indication, according to the company. The approval follows a series of studies that identified only mild to moderate adverse events.

Symbiomix will launch the drug in the first quarter of 2018.

View today's stories